SpyGlass Pharma (SGP) director reports 65,976 stock options holding

Rhea-AI Filing Summary

SpyGlass Pharma director Elizabeth G. O'Farrell reported her beneficial ownership of stock options in the company. She holds a stock option for 65,976 shares of common stock with an exercise price of $7.11 per share, expiring on August 5, 2035.

According to the vesting terms, starting from a Vesting Commencement Date of August 6, 2025, 25% of the option vests on the one-year anniversary, with the remaining shares vesting in equal monthly installments over the following 36 months, subject to her continued service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider O'Farrell Elizabeth G.

Role Director

Type	Security	Shares	Price	Value
holding	Stock Option (right to buy)	--	--	--

Holdings After Transaction: Stock Option (right to buy) — 65,976 shares (Direct)

Footnotes (1)

1. [object Object]

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

O'Farrell Elizabeth G.

(Last) (First) (Middle)

C/O SPYGLASS PHARMA, INC.

27061 ALISO CREEK RD., SUITE 100

(Street)

ALISO VIEJO CA 92656

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
02/05/2026

3. Issuer Name and Ticker or Trading Symbol
SpyGlass Pharma, Inc. [ SGP ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	(1)	08/05/2035	Common Stock	65,976	$7.11	D

Explanation of Responses:

1. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan) through each applicable date, twenty-five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean August 6, 2025.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Brian Aukshunas, as Attorney-in-Fact	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does SpyGlass Pharma (SGP) director Elizabeth O'Farrell report in this Form 3?

Elizabeth G. O'Farrell reports beneficial ownership of a stock option for 65,976 shares of SpyGlass Pharma common stock. The option has a $7.11 exercise price and an August 5, 2035 expiration, reflecting her derivative equity position as a company director.

How many SpyGlass Pharma (SGP) shares are covered by Elizabeth O'Farrell's option?

Her reported stock option covers 65,976 shares of SpyGlass Pharma common stock. This derivative holding gives her the right to buy those shares at a fixed $7.11 exercise price before the option’s August 5, 2035 expiration date, subject to the vesting schedule.

What is the exercise price and expiration date of Elizabeth O'Farrell's SpyGlass Pharma option?

The stock option held by Elizabeth O'Farrell carries a $7.11 per share exercise price and expires on August 5, 2035. These terms define the cost to purchase SpyGlass Pharma common stock and the final date by which the option can be exercised.

How does Elizabeth O'Farrell's SpyGlass Pharma option vest over time?

The option vests based on continued service. Twenty-five percent of the shares vest on the one-year anniversary of the August 6, 2025 Vesting Commencement Date, with the remaining shares vesting in equal monthly installments over the next 36 months, if service continues.

What does the Vesting Commencement Date mean for SpyGlass Pharma director options?

The Vesting Commencement Date, August 6, 2025, starts the vesting schedule for the option. One year later, 25% of the shares vest, and the rest vest in 36 equal monthly installments, assuming the director remains a service provider to SpyGlass Pharma.